Intravitreal Tissue Plasminogen Activator Injection for the Treatment of Proliferative Vitreoretinopathy in a Rabbit Model
Author: Assaf Dotan (Israel)
Co-authors: Olga Reitblat, Eduard Barayev, Orly Gal-Or, Maria Tsessler
Purpose
To evaluate the effect of intravitreal injection of tissue plasminogen activator (tPA) on proliferative vitreoretinopathy (PVR).
Setting/Venue
Felsenstein Medical Research Center, Tel Aviv University, Israel.
Methods
Experimental PVR was induced in the right eye of rabbits by intraocular injection of dispase (0.05 U/0.1 mL). Progression of PVR was followed by indirect ophthalmic examination. Six weeks after Dispase injection, animals were divided to receive intravitreal injection of either 25 µg/0.1 mL tPA or balanced salt solution (BSS). Animals were euthanized at 48 hours following tPA/BSS injection and eyes were enucleated for histological evaluation. Immunostaining for fibroblasts using Mouse Monoclonal anti Rabbit α-smooth muscle actin (αSMA) and staining for collagen using Sirius Red were performed.
Results
: Five PVR model eyes were injected with tPA and four with BSS. Following tPA injection, one eye had a reduction in PVR from grade 2 to 1, three eyes remained stable and in one eye the severity of PVR couldn't be assessed due to limited view. In the BSS group, PVR grade was unchanged in three eyes and couldn't be visualized in one eye. Staining of histological specimens with αSMA showed a reduced presence of fibroblasts in eyes injected with tPA compared with those injected with BSS. In addition, collagen type I and III, demonstrated by Sirius Red staining, was reduced in the tPA group in comparison to controls.
Conlusions
Our results suggest that intravitreally injected tPA may show an inhibitory effect on PVR progression. This experiment provides a scientific rationale for further exploration of the use of intravitreal tPA for the treatment of PVR in clinical trials.